GlobeNewswire Inc.Sep 14, 1:00 PM ET▲ Positive
Resecabtagene autoleucel (CABA-201) is in clinical development as a CAR-T therapy for lupus nephritis, positioning the company in the innovative treatment pipeline.
Cabaletta Bio news
$1.98−1.00%
Close Sep 29, 2026 · split-adjustedArticles · 30 days1English, de-duplicated
Positive1100% of coverage
Neutral00%
Negative00% of coverage
About Cabaletta Bio
No recent articles focused on Cabaletta Bio.
Also mentions CABA
Articles that tag CABA but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology